On the other hand, the effects of fecal calprotectin (FCP), Crohn’s Disease Activity Index (CDAI) score, partial Mayo score, age, prior TNF-α antagonist therapy status, ADA status (ELISA assay), and concomitant therapy use on VDZ CLL were not considered clinically important in the Rosario et al. model [11], and Bayesian 95% credible intervals 95% (CDIs) for most effects contained the null effect. This evidence concerns the gene ADA and Crohn disease.